Parkinsonian Disorders: Clinical Trials

443 trials for Parkinsonian Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

281 completed, 47 recruiting, 36 unknown, 27 terminated. 443 Phase 1, 107 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1443Completed 281, Recruiting 47, Unknown 36, Terminated 27, Not yet recruiting 19, Withdrawn 16, Active not recruiting 13, Enrolling by invitation 3, Suspended 1
Phase 2107Completed 51, Recruiting 15, Unknown 11, Terminated 9, Active not recruiting 7, Not yet recruiting 7, Withdrawn 5, Enrolling by invitation 1, Suspended 1

Follow Parkinsonian Disorders: new trials by email Literature Review of Parkinsonian Disorders trials Research Report on Parkinsonian Disorders

Trials (filtered) newest first · largest first

All 443 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Terazosin for Dementia With Lewy Bodies
Terazosin Hydrochloride, Placebo - Dementia With Lewy Bodies
Phase 1 / Phase 2Not yet recruitingQiang Zhang402027-10-012026-03-12
Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease
Fecal Microbiota Transplant - Parkinson Disease
Phase 1Not yet recruitingProgenaBiome102027-07-012026-10-09
Sustained Release Oral Formulation For Treatment Of Parkinsons Disease
Formulation A, Formulation B, Formulation C - Healthy Volunteers
Phase 1 / Phase 2Not yet recruitingUniversity of Minnesota322027-04-012026-10-01
Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study
Injecting KL002 into the bilateral putamen - Parkinson's Disease (PD), Advanced Primary PD
Phase 1 / Phase 2Not yet recruitingKanglin Biotechnology (Hangzhou) Co., Ltd.122027-01-012026-11-16
ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's Disease
ZR001 - Parkinson's Disease (PD), Parkinsonian Disorders
Phase 1Not yet recruitingQianfoshan Hospital82026-12-012026-07-22
Coordinated Reset Deep Brain Stimulation for Parkinson's Disease
DBS - Parkinson's Disease (PD), Deep Brain Stimulation
Phase 1Not yet recruitingUniversity of Minnesota242026-12-012026-10-13
Stanford University Neurofiber Study
Prebiotic fiber bar - PARKINSON DISEASE (Disorder)
Phase 1Not yet recruitingStanford University502026-12-012026-11-03
A Phase 1/2a Clinical Study of KL002 in Treatment of Parkinson's Disease
Injecting KL002 into the bilateral putamen - Parkinson's Disease (PD), PD
Phase 1 / Phase 2Not yet recruitingKanglin Biotechnology (Hangzhou) Co., Ltd.122026-12-012026-11-10
A Phase 1 Study of NCR201 in Parkinson's Disease Patients With Prior DBS
NCR201 - PARKINSON DISEASE (Disorder), Cell Therapy
Phase 1Not yet recruitingNuwacell Biotechnologies Co., Ltd.122026-11-012026-10-26
AAV2-hAADC for Parkinson's Disease (PDCS-01)
AAV2-hAADC - Parkinson's Disease (PD), Early Onset Parkinson Disease
Phase 1Not yet recruitingRussell Lonser92026-11-012026-11-03
Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial
Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy
Phase 1 / Phase 2RecruitingPrabesh Kanel152026-10-012026-11-05
Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease
UX-DA003 - Parkinson's Disease
Phase 1 / Phase 2RecruitingShanghai UniXell Biotechnology Co., Ltd122026-09-242026-11-04
Assessment of the Safety, Immunogenicity, and Pharmacodynamics of TRB-001 in Patients With Early Idiopathic Parkinson's Disease
TRB-001, Placebo - Parkinson Disease (PD), Idiopathic Parkinson's Disease
Phase 1RecruitingTridem Bioscience FlexCo362026-09-012026-09-24
Terazosin And Metabolic Engagement in Parkinson's Disease
Terazosin Hydrochloride, Placebo - Parkinson's Disease
Phase 1 / Phase 2WithdrawnNandakumar Narayanan2026-09-012026-10-07
MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD)
[¹⁸F]MK-0947 - Parkinsons Disease (PD), Healthy Elderly Volunteers
Phase 1RecruitingXingImaging, LLC182026-08-252026-10-19
An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination.
TRB-001 - Parkinson's Disease
Phase 1RecruitingTridem Bioscience FlexCo62026-07-282026-09-10
A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA
SST001 - Multiple System Atrophy (MSA), Parkinson's Disease (PD)
Phase 1RecruitingSynusight Biotech (Shanghai) Co., Ltd.302026-06-152026-09-01
A Clinical Study to Evaluate the Safety of MF1, a New Treatment for Parkinson's Disease-related Disorders (MF1 Study)
MF-1, Placebo - Healthy Adult Male, PARKINSON DISEASE (Disorder)
Phase 1RecruitingUniversity of Shizuoka582026-06-012026-06-24
A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)
Lu AF28996 - Parkinson Disease
Phase 1RecruitingH. Lundbeck A/S102026-05-262026-08-10
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations
VGN-R08b 4.2×10^13 vg, VGN-R08b 8.4×10^13 vg, VGN-R08b 1.68×10^14 vg - Parkinson Disease (PD)
Phase 1 / Phase 2Not yet recruitingShanghai Vitalgen BioPharma Co., Ltd.172026-05-252026-05-01

Showing 20 of 443. Sign in to see all of them.

Narrower conditions

Parkinson Disease (436)  ·  Movement Disorders (19)  ·  Alzheimer Disease (18)  ·  Neurodegenerative Diseases (16)  ·  Multiple System Atrophy (13)  ·  Dyskinesias (11)  ·  Lewy Body Disease (10)  ·  Brain Diseases (8)  ·  Central Nervous System Diseases (7)  ·  Cognitive Dysfunction (7)  ·  Depression (6)  ·  Nervous System Diseases (6)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (6)  ·  Amyotrophic Lateral Sclerosis (4)

Broader conditions

Basal Ganglia Diseases (440)  ·  Synucleinopathies (440)  ·  Nervous System Diseases (437)  ·  Central Nervous System Diseases (436)  ·  Brain Diseases (435)  ·  Neurodegenerative Diseases (426)  ·  Movement Disorders (424)  ·  Mental Disorders (34)  ·  Neurocognitive Disorders (32)  ·  Pathological Conditions, Signs and Symptoms (32)  ·  Signs and Symptoms (28)  ·  Dementia (24)  ·  Neurologic Manifestations (24)  ·  Autonomic Nervous System Diseases (15)

Interventions

opicapone (29)  ·  carbidopa, levodopa drug combination (21)  ·  Levodopa (14)  ·  Carbidopa (12)  ·  rotigotine (12)  ·  entacapone (11)  ·  nebicapone (9)  ·  benserazide, levodopa drug combination (6)  ·  Resveratrol (4)  ·  Sodium Chloride (4)  ·  rasagiline (4)  ·  2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine (3)  ·  3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole (3)  ·  Acetylcysteine (3)  ·  Rifaximin (3)

Sponsors

Bial - Portela C S.A. (44)  ·  Luye Pharma Group Ltd. (11)  ·  Institute for Neurodegenerative Disorders (9)  ·  H. Lundbeck A/S (8)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (8)  ·  NeuroDerm Ltd. (7)  ·  AbbVie (5)  ·  Affiris AG (5)  ·  Kyowa Kirin Co., Ltd. (5)  ·  Merck Sharp & Dohme LLC (5)  ·  Pfizer (5)  ·  University of Minnesota (5)  ·  Craig van Horne, MD, PhD (4)  ·  Herantis Pharma Plc. (4)  ·  Neurocrine Biosciences (4)

Countries

United States (197)  ·  China (38)  ·  United Kingdom (30)  ·  France (22)  ·  Portugal (16)  ·  Germany (15)  ·  Netherlands (15)  ·  Canada (14)  ·  Japan (14)  ·  Sweden (10)  ·  Finland (9)  ·  Australia (8)  ·  Israel (8)  ·  Austria (7)  ·  South Korea (7)

Top investigators

Danna Jennings, MD (4)  ·  Craig van Horne, MD, PhD (3)  ·  Nicolaas I Bohnen, MD, PhD (3)  ·  Charles Oh, MD (2)  ·  David Russell, MD (2)  ·  David Russell, MD, PhD (2)

Results publications

PMID 40680102, PMID 30741694, PMID 31127735, PMID 36602886, PMID 38588457, PMID 10816186, PMID 23860343, PMID 24412048, PMID 29862060, PMID 30361858, PMID 35949912, PMID 38072889, PMID 11408093, PMID 12112073, PMID 12672864, PMID 1362956, PMID 1454205, PMID 16324089, PMID 16941456, PMID 17586305, PMID 18387850, PMID 18416667, PMID 18650802, PMID 18695057, PMID 19029430, PMID 19077238, PMID 19230029, PMID 19491335, PMID 20065126, PMID 20213818, PMID 20228251, PMID 20734360, PMID 20925125, PMID 20946640, PMID 21474638, PMID 21484351, PMID 21795440, PMID 21834011, PMID 22334107, PMID 22401642, PMID 23229334, PMID 23240940, PMID 23576625, PMID 24006953, PMID 25689258, PMID 25791613, PMID 26171276, PMID 27153166, PMID 27213850, PMID 27591395

NIH funding

2014 (6), 2009 (2), 2015 (2), 2019 (2), 2025 (2), R01NS099535 (2), 2001 (1), 2016 (1), 2017 (1), 2018 (1), 2023 (1), I01RX003397 (1), IK2RX002938 (1), K01AT004404 (1), M01RR000096 (1)